6 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
6 Nov 19
Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019
9:28am
. One participant discontinued therapy due to mild, treatment-related hypereosinophilia and one participant died from injuries as a passenger in a car
424B5
RYTM
Rhythm Pharmaceuticals Inc.
16 Oct 19
Prospectus supplement for primary offering
5:25pm
, or SAEs, related to treatment with setmelanotide.
One LEPR study patient died from injuries unrelated to the study drug. This patient … was a passenger in a vehicle in a car accident and died from injuries from the accident.
We believe we are on track to complete submission of a rolling NDA
424B5
RYTM
Rhythm Pharmaceuticals Inc.
15 Oct 19
Prospectus supplement for primary offering
4:51pm
to treatment with setmelanotide.
One LEPR study patient died from injuries unrelated to the study drug. This patient was a passenger in a vehicle … in a car accident and died from injuries from the accident.
We believe we are on track to complete submission of a rolling NDA to the FDA that will cover
8-K
EX-99.1
kutho2j31q8s
7 Aug 19
Other Events
9:07am
- Prev
- 1
- Next